GSK shrinks Scynexis deal after delay in commercialization of antifungal drug

Scynex­is will get less mon­ey in a mul­ti­mil­lion-dol­lar li­cense agree­ment with Glax­o­SmithK­line af­ter po­ten­tial cross-con­t­a­m­i­na­tion in the man­u­fac­tur­ing of its an­ti­fun­gal drug de­layed com­mer­cial­iza­tion.

Scynex­is said in SEC fil­ings it has al­ready re­ceived an up­front pay­ment of $90 mil­lion and one de­vel­op­ment mile­stone pay­ment of $25 mil­lion in the deal to li­cense ibrex­a­fungerp, ap­proved as Brex­afemme to treat vagi­nal yeast in­fec­tions, to GSK. GSK will al­so pay roy­al­ties based on an­nu­al sales, the terms of which were left un­changed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.